Edition:
United States

pSivida Corp (PSDV.OQ)

PSDV.OQ on NASDAQ Stock Exchange Global Market

1.25USD
22 Sep 2017
Change (% chg)

$0.03 (+2.46%)
Prev Close
$1.22
Open
$1.24
Day's High
$1.25
Day's Low
$1.21
Volume
57,111
Avg. Vol
84,968
52-wk High
$3.37
52-wk Low
$1.04

Select another date:

Mon, Sep 11 2017

BRIEF-pSivida Corp reports Q4 loss per share $0.16

* pSivida Corp achieves significant milestones throughout fy 2017; reports fourth quarter and fiscal 2017 results

BRIEF-pSivida- in connection with new collaboration agreement, Alimera forgave $10 mln of co's share of losses associated with commercialization of ILUVIEN

* pSivida - in connection with new collaboration agreement, alimera forgave $10 million of co's share of losses associated with commercialization of ILUVIEN

BRIEF-Psivida out-licenses EMEA rights for Durasert three-year treatment for posterior segment Uveitis

* Psivida out-licenses emea rights for durasert™ three-year treatment for posterior segment uveitis while retaining u.s. Commercial rights; amended global collaboration agreement with alimera for iluvien® improves psivida’s revenue generation

BRIEF-Psivida submits marketing authorization application for approval of Durasert in EU

* Psivida submits marketing authorization application (maa) for approval of durasert™ three-year treatment for posterior segment uveitis in European Union

BRIEF-Psivida's Durasert successfully achieves primary efficacy endpoint in second phase 3 study

* Psivida's Durasert three-year treatment for posterior segment uveitis successfully achieves primary efficacy endpoint in second phase 3 study

BRIEF-Pfizer reports 4.7 pct stake in pSivida Corp as of May 15 - SEC filing

* Pfizer Inc reports 4.7 percent stake in pSivida Corp, as of May 15, 2017 - SEC filing

BRIEF-pSivida announces positive 12-month follow-up data for Durasert three-year treatment for posterior segment uveitis

* Psivida corp- durasert™ three-year treatment for posterior segment uveitis significantly reduces recurrences through 12 months

BRIEF-Psivida Q3 loss per share $0.15

* Psivida Corp reports fiscal 2017 third quarter results; key milestones on track

BRIEF-Rosalind Advisors reports 6.2 pct passive stake in pSivida as of April 5 - SEC filing

* Rosalind Advisors Inc reports a 6.2 percent passive stake in pSivida Corp as of April 5 - SEC filing Source text : (http://bit.ly/2oNkBw7) Further company coverage:

Select another date: